Aptinyx Inc. APTX
We take great care to ensure that the data presented and summarized in this overview for Aptinyx Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in APTX
Top Purchases
Top Sells
About APTX
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II/b clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase II/b clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase II clinical study for the treatment of Parkinson's disease cognitive impairment. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
Insider Transactions at APTX
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 13
2022
|
Joan W. Miller |
BUY
Open market or private purchase
|
Direct |
17,700
+50.0%
|
$35,400
$2.83 P/Share
|
|
Dec 06
2021
|
Norbert G Riedel EXECUTIVE CHAIRMAN OF THE BOD |
BUY
Open market or private purchase
|
Indirect |
100,000
+50.0%
|
$200,000
$2.23 P/Share
|
|
Dec 02
2021
|
Ashish Khanna CFO AND CBO |
BUY
Open market or private purchase
|
Direct |
45,000
+9.68%
|
$90,000
$2.26 P/Share
|
|
Nov 12
2021
|
Robert J. Hombach |
BUY
Open market or private purchase
|
Direct |
74,600
+25.4%
|
$149,200
$2.4 P/Share
|
|
Nov 11
2021
|
Robert J. Hombach |
BUY
Open market or private purchase
|
Direct |
5,400
+3.6%
|
$10,800
$2.4 P/Share
|
|
May 17
2021
|
Norbert G Riedel EXECUTIVE CHAIRMAN OF THE BOD |
SELL
Payment of exercise price or tax liability
|
Direct |
127,274
-17.14%
|
$254,548
$2.53 P/Share
|
|
May 17
2021
|
Norbert G Riedel EXECUTIVE CHAIRMAN OF THE BOD |
BUY
Exercise of conversion of derivative security
|
Direct |
380,000
+33.85%
|
-
|
|
May 17
2021
|
Ashish Khanna CFO AND CBO |
SELL
Payment of exercise price or tax liability
|
Direct |
38,090
-9.22%
|
$76,180
$2.53 P/Share
|
|
May 17
2021
|
Ashish Khanna CFO AND CBO |
BUY
Exercise of conversion of derivative security
|
Direct |
130,000
+23.94%
|
-
|
|
May 17
2021
|
Andrew Kidd PRESIDENT AND CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
38,090
-27.38%
|
$76,180
$2.53 P/Share
|
|
May 17
2021
|
Andrew Kidd PRESIDENT AND CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
130,000
+48.3%
|
-
|
|
Oct 26
2020
|
Bain Capital Life Sciences Investors, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
3,333,333
+27.27%
|
$9,999,999
$3.0 P/Share
|
|
Jul 09
2020
|
Adams Street Partners LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
90,124
+24.67%
|
-
|
|
Jan 29
2020
|
Adams Street Partners LLC > 10% Shareholder |
BUY
Other acquisition or disposition
|
Indirect |
90,124
+32.74%
|
-
|
|
Jan 10
2020
|
Adams Street Partners LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,000,000
+18.67%
|
$3,000,000
$3.0 P/Share
|
|
Jun 25
2018
|
Adams Street Partners LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
150,000
+4.28%
|
$2,400,000
$16.0 P/Share
|
|
Jun 25
2018
|
Adams Street Partners LLC > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,040,077
+33.2%
|
-
|